Recent

% | $
Quotes you view appear here for quick access.

VPHM Message Board

  • lennox64 lennox64 Sep 24, 2012 6:02 PM Flag

    Price Targets and Upgrades

    Bank of America boosted their price target on shares of ViroPharma Incorporated (NASDAQ: VPHM) from $25.00 to $35.00 in a research note issued on Monday. The firm currently has a “neutral” rating on the stock.

    The analysts wrote, “In light of VPHM’s 2015 financial targets, we are increasing our revenue/EPS estimates for 2013+ to reflect better European sales for two newer drugs, Buccolam and Plenadren. Our PO increases from $25 to $35 on these estimates, and additional upside is possible if VPHM’s pipeline development is successful (maribavir for CMV interesting). Nonetheless, VPHM has a limited track record in Europe (initial EU Cinryze uptake has been extremely modest), and nearly all of our model changes are inter-dependent and driven by VPHM’s EU performance expectations: (1) Plenadren sales of $200M implies EU market penetration of 10-30% in a market dominated by generics (see table 1), (2) profitability of EU business in 2014 is dependent on sales assumptions, (3) lower tax rate is predicated on EU-based products in lower tax jurisdictions. We view 2013 as a critical time for the launch trajectory to build confidence in these projections, but believe that management’s ability to execute on its outlook could drive significant valuation upside over the next few years. We maintain our Neutral rating pending greater conviction in VPHM’s outlook.”

    Several other analysts have also recently commented on the stock. Analysts at Jefferies Group raised their price target on shares of ViroPharma Incorporated from $29.00 to $40.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Separately, analysts at Wells Fargo & Co. upgraded shares of ViroPharma Incorporated from a “market perform” rating to an “outperform” rating in a research note to investors on Monday. Finally, analysts at Deutsche Bank reiterated a “buy” rating on shares of ViroPharma Incorporated in a research note to investors on Thursday. They now have a $37.00 price target on the stock.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "We view 2013 as a critical time for... THE LAUNCH TRAJECTORY!... to build confidence in these projections, but believe that management’s ability to execute on its outlook could drive significant valuation... UPSIDE!... over the next few years."

      to da mooon! baaby... To DA MOOON!.....
      yeeeehaaahhh!!....

      aloha,
      kamoa